Q-omics provides the consensus-scored FAM160A1-DT profile across patient tissues and cancer cell-line models. FAM160A1-DT expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, FAM160A1-DT is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, FAM160A1-DT RNA expression shows 18,842 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KICH, KIRC, and THYM as cancer lineages where FAM160A1-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM160A1-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM160A1-DT survival associations across molecular data types. FAM160A1-DT RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM160A1-DT RNA expression–survival associations across cancer types. High FAM160A1-DT expression shows unfavorable associations in KICH, HNSC and LGG, but favorable associations in READ, KIRC and BRCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KICH as the clearest survival context for FAM160A1-DT RNA expression.
This table summarizes FAM160A1-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM160A1-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM160A1-DT shows lower tumor expression in KIRC, KICH and COAD and higher tumor expression in STAD, HNSC and BRCA. The KIRC box plot shows higher FAM160A1-DT RNA expression in normal versus tumor tissue (log2 FC = −0.655, t-test p < 0.001).
This table shows molecular features associated with FAM160A1-DT in patient tissues and cancer cell lines. In patient samples, FAM160A1-DT shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
